TY - JOUR
T1 - Interaction of immunoglobulin with cytomegalovirus-infected cells
AU - Aiba, Nobuyasu
AU - Shiraki, Atsuko
AU - Yajima, Misako
AU - Oyama, Yukari
AU - Yoshida, Yoshihiro
AU - Ohno, Ayumu
AU - Yamada, Hiroshi
AU - Takemoto, Masaya
AU - Daikoku, Tohru
AU - Shiraki, Kimiyasu
N1 - Funding Information:
This work was partly supported by grants from JSPS KAKENHI Grant No. 25293108 from the Ministry of Education, Culture, Sports, Science and Technology of Japan and Japan Blood Products Organization. The authors thank Ms. Katherine Ono for editing this article.
Publisher Copyright:
© Copyright 2017, Mary Ann Liebert, Inc. 2017.
PY - 2017/9
Y1 - 2017/9
N2 - Intravenous immunoglobulin (IVIG) is used to treat or prevent severe viral infection, especially cytomegalovirus (CMV) infections. IVIG was characterized to understand its interaction with CMV-infected cells. IVIG retarded CMV spread and reduced virus yields depending on the neutralizing (NT) antibody titer. Immediate early protein synthesis was reduced by IVIG in 3 to 15 h, and IVIG specifically reduced the ratio of 66/68k protein synthesis among immediate early proteins in an NT antibody-dependent manner between 4 and 8 h after infection, indicating that antigenic modulation of CMV-infected cells by IVIG reduced viral protein synthesis and virus production. The half-life of antibody bound to CMV-infected cells was 3.8 h. NT antibody titers to varicella-zoster virus (VZV) and CMV in IVIG were dose dependently absorbed by cells infected with VZV and CMV, respectively, but the antibody titers to CMV and VZV, respectively, were not affected. NT antibody in 0.3 mL of IVIG (15 mg) was specifically absorbed by 10 8 CMV-infected cells and 10 7 VZV-infected cells, suggesting that the NT antibody in IVIG might be inactivated by one-tenth of a similar volume of CMV-infected or VZV-infected cells. Various antiviral activities of IVIG may contribute to control and alleviation of CMV infection.
AB - Intravenous immunoglobulin (IVIG) is used to treat or prevent severe viral infection, especially cytomegalovirus (CMV) infections. IVIG was characterized to understand its interaction with CMV-infected cells. IVIG retarded CMV spread and reduced virus yields depending on the neutralizing (NT) antibody titer. Immediate early protein synthesis was reduced by IVIG in 3 to 15 h, and IVIG specifically reduced the ratio of 66/68k protein synthesis among immediate early proteins in an NT antibody-dependent manner between 4 and 8 h after infection, indicating that antigenic modulation of CMV-infected cells by IVIG reduced viral protein synthesis and virus production. The half-life of antibody bound to CMV-infected cells was 3.8 h. NT antibody titers to varicella-zoster virus (VZV) and CMV in IVIG were dose dependently absorbed by cells infected with VZV and CMV, respectively, but the antibody titers to CMV and VZV, respectively, were not affected. NT antibody in 0.3 mL of IVIG (15 mg) was specifically absorbed by 10 8 CMV-infected cells and 10 7 VZV-infected cells, suggesting that the NT antibody in IVIG might be inactivated by one-tenth of a similar volume of CMV-infected or VZV-infected cells. Various antiviral activities of IVIG may contribute to control and alleviation of CMV infection.
KW - ADCC
KW - antigenic modulation
KW - cytomegalovirus
KW - intravenous immunoglobulin
KW - varicella-zoster virus
UR - http://www.scopus.com/inward/record.url?scp=85058231539&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85058231539&partnerID=8YFLogxK
U2 - 10.1089/vim.2016.0151
DO - 10.1089/vim.2016.0151
M3 - Article
C2 - 28598267
AN - SCOPUS:85058231539
SN - 0882-8245
VL - 30
SP - 500
EP - 507
JO - Viral Immunology
JF - Viral Immunology
IS - 7
ER -